Short-course beta-lactam treatment for community-acquired pneumonia

Comment

. 2004 Mar 1;38(5):766-7.

doi: 10.1086/381761.

Comment

Kristoffer Stralin et al. Clin Infect Dis. 2004.

. 2004 Mar 1;38(5):766-7.

doi: 10.1086/381761.

No abstract available

Comment on

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, Wiesinger BA, Xiang JX, Zadeikis N, Kahn JB. Dunbar LM, et al. Clin Infect Dis. 2003 Sep 15;37(6):752-60. doi: 10.1086/377539. Epub 2003 Aug 28. Clin Infect Dis. 2003. PMID: 12955634 Clinical Trial.

Decrease in drug resistance in pneumococcal community-acquired pneumonia.
Obando I, Arroyo L, Sanchez-Tatay D. Obando I, et al. Chest. 2007 Jul;132(1):359; author reply 359-60. doi: 10.1378/chest.06-2363. Chest. 2007. PMID: 17625101 No abstract available.
Role of beta-lactam agents in the treatment of community-acquired pneumonia.
Garau J. Garau J. Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):83-99. doi: 10.1007/s10096-005-1287-9. Eur J Clin Microbiol Infect Dis. 2005. PMID: 15696306 Review.
[New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M. Egger M. Dtsch Med Wochenschr. 2003 May 9;128(19):1071. doi: 10.1055/s-2003-39105. Dtsch Med Wochenschr. 2003. PMID: 12736860 German. No abstract available.
[Resistance to penicillin and erythromycin of Streptococcus pneumoniae and Streptococcus pyogenes isolated from community-acquired respiratory infections in Spain between 1986-1999 and its relationship with the use of beta-lactams and macrolides].
Granizo Martínez JJ. Granizo Martínez JJ. Rev Esp Quimioter. 2005 Mar;18(1):83-5. Rev Esp Quimioter. 2005. PMID: 15915241 Spanish. No abstract available.
Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
Feldman C. Feldman C. J Lab Clin Med. 2004 May;143(5):269-83. doi: 10.1016/j.lab.2004.02.002. J Lab Clin Med. 2004. PMID: 15122171 Review.